Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: Incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers

Journal of Critical Care

Volumn 30, Issue 2, 2015, Pages 276-281

  Frantzeskaki, Frantzeska G ^a   Karampi, Eirini Sofia ^a   Kottaridi, Christina ^a   Alepaki, Maria ^a   Routsi, Christina ^b   Tzanela, Marinella ^c   Vassiliadi, Dimitra Argyro ^a   Douka, Evangelia ^b   Tsaousi, Sofia ^b   Gennimata, Vasiliki ^e   Ilias, Ioannis ^d   Nikitas, Nikitas ^a   Armaganidis, Apostolos ^a   Karakitsos, Petros ^a   Papaevangelou, Vassiliki ^e   Dimopoulou, Ioanna ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d Elena Hospital   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Critical illness; Cytomegalovirus; Inflammatory biomarkers; Multiorgan dysfunction

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CORTISOMOL; CYTOKINE; VIRUS DNA; ZINC OXIDE EUGENOL;

ADULT; AGED; APACHE; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; CRITICAL ILLNESS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; IMMUNOCOMPETENCE; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SALIVA ANALYSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; TREATMENT DURATION; UPREGULATION; VIRUS DETECTION; VIRUS REACTIVATION; ADOLESCENT; BLOOD; CHEMISTRY; CYTOMEGALOVIRUS INFECTIONS; GENETICS; IMMUNOLOGY; MIDDLE AGED; ORGAN DYSFUNCTION SCORE; PHYSIOLOGY; SALIVA; VERY ELDERLY; VIRUS ACTIVATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CRITICAL ILLNESS; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HUMANS; IMMUNOCOMPETENCE; INCIDENCE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; ORGAN DYSFUNCTION SCORES; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RESPIRATION, ARTIFICIAL; RISK FACTORS; SALIVA; VIRUS ACTIVATION; YOUNG ADULT; ZINC OXIDE-EUGENOL CEMENT;

EID: 84923004089     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2014.10.002     Document Type: Article

References (30)

1. Sweet C. The pathogenicity of cytomegalovirus. FEMS Microbiol Rev 1999, 23(4):457-482.
2. Jaber S., Chanques G., Borry J., Souche B., Verdier R., Perrigault P.F., et al. Cytomegalovirus infection in critically ill patients: associated factors and consequences. Chest 2005, 127(1):233-241.
3. Hamprecht K., Maschmann J., Vochem M., Dietz K., Speer C.P., Jahn G. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 2001, 357(9255):513-518.
4. Schrier R.D., Nelson J.A., Oldstone M.B. Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science 1985, 230(4729):1048-1051.
5. Rafailidis P.I., Mourtzoukou E.G., Varbobitis I.C., Falagas M.E. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J 2008, 5:47-54.
6. Osawa R., Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care 2009, 13(3):R68-R78.
7. Limaye A.P., Kirby K.A., Rubenfeld G.D., Leisenring W.M., Bulger E.M., Neff M.J., et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008, 300(4):413-422.
8. Kutza A.S., Muhl E., Hackstein H., Kirchner H., Bein G. High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 1998, 26(5):1076-1082.
9. Tamion F., Richard V., Lyoumi S., Daveau M., Bonmarchand G., Leroy J., et al. Gut ischemia and mesenteric synthesis of inflammatory cytokines after hemorrhagic or endotoxic shock. Am J Physiol 1997, 273(2 Pt 1):G314-G321.
10. Varani S., Landini M.P. Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae 2011, 2(1):6-16.
11. Docke W.D., Prosch S., Fietze E., Kimel V., Zuckermann H., Klug C., et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet 1994, 343(8892):268-269.
12. Bone R.C. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996, 24(7):1125-1128.
13. Arafah B.M., Nishiyama F.J., Tlaygeh H., Hejal R. Measurement of salivary cortisol concentration in the assessment of adrenal function in critically ill subjects: a surrogate marker of the circulating free cortisol. J Clin Endocrinol Metab 2007, 92(8):2965-2971.
14. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39(2):165-228.
15. .
16. Hanley J.A., McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148(3):839-843.
17. De Vlieger G., Meersseman W., Lagrou K., Wouters P., Wilmer A., Peetermans W.E., et al. Cytomegalovirus serostatus and outcome in nonimmunocompromised critically ill patients. Crit Care Med 2012, 40(1):36-42.
18. Papazian L., Fraisse A., Garbe L., Zandotti C., Thomas P., Saux P., et al. Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia. Anesthesiology 1996, 84(2):280-287.
19. Mutimer D., Mirza D., Shaw J., O'Donnell K., Elias E. Enhanced (cytomegalovirus) viral replication associated with septic bacterial complications in liver transplant recipients. Transplantation 1997, 63(10):1411-1415.
20. Gogos C.A., Drosou E., Bassaris H.P., Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000, 181(1):176-180.
21. Gandhi M.K., Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004, 4(12):725-738.
22. Heininger A., Haeberle H., Fischer I., Beck R., Riessen R., Rohde F., et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. Crit Care 2011, 15(2):R77-R87.
23. Zhu H., Cong J.P., Yu D., Bresnahan W.A., Shenk T.E. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc Natl Acad Sci U S A 2002, 99(6):3932-3937.
24. Varani S., Frascaroli G., Homman-Loudiyi M., Feld S., Landini M.P., Soderberg-Naucler C. Human cytomegalovirus inhibits the migration of immature dendritic cells by down-regulating cell-surface CCR1 and CCR5. J Leukoc Biol 2005, 77(2):219-228.
25. Bowden R.A., Slichter S.J., Sayers M., Weisdorf D., Cays M., Schoch G., et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995, 86(9):3598-3603.
26. Nichols W.G., Price T.H., Gooley T., Corey L., Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003, 101(10):4195-4200.
27. Trinchieri G. Regulation of tumor necrosis factor production by monocyte-macrophages and lymphocytes. Immunol Res 1991, 10(2):89-103.
28. Jain M., Duggal S., Chugh T.D. Cytomegalovirus infection in non-immunosuppressed critically ill patients. J Infect Dev Ctries 2011, 5(8):571-579.
29. Heininger A., Jahn G., Engel C., Notheisen T., Unertl K., Hamprecht K. Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit Care Med 2001, 29(3):541-547.
30. Chiche L., Forel J.M., Roch A., Guervilly C., Pauly V., Allardet-Servent J., et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med 2009, 37(6):1850-1857.